Recently, Hibiocy, a partner of GenScript, received approval from Thai FDA for its nasal spray named VAILL COVITRAP™ and is working on its commercialization.
COVITRAP™ is capable of preventing the COVID-19 virus from attaching to the internal surfaces of the nasal cavity and thus reduces the viral load in the cavity. This offers extra protection against the COVID-19 virus. The human anti-SARS-CoV-2 antibodies which are a crucial part of the VAILL COVITRAP™ nasal spray device were developed by Dr. Trairak Pisitkun’s team from Chulalongkorn University, Bangkok, Thailand. GenScript has supported the team with antibody production and characterization during the early phase of research and contributed to the development of VAILL COVITRAP™. The antibodies were licensed to Hibiocy Co. Ltd., which further developed them into VAILL COVITRAP™.
Human anti-SARS-CoV-2 antibodies and VAILL COVITRAP™
On October 17, GenScript ProBio and Hibiocy entered into strategic collaboration for the development and manufacturing of COVITRAP™ and future new products. Hibiocy is working to launch the COVITRAP™ nasal spray device in other countries as well. GenScript ProBio will be the exclusive service partner for the upcoming commercial manufacturing. Aside from the COVITRAP™ project, both parties are planning to set off a future long-term collaboration for new products and manufacturing in the near future. Under this agreement, GenScript ProBio will be the exclusive service partner of Hibiocy from clinical material manufacturing to commercial manufacturing and provide professional consultation for new products. Top priority to access GMP service will be granted to Hibiocy to accelerate the antibody drug development.
On November 1, GenScript further announced long-term collaboration with Biogenexis, a biotechnology company established by the team from Chulalongkorn University to develop bleeding-edge biomedical innovation, which includes therapeutic antibodies, advanced skin care products, vaccine-related materials and IVD kit development and manufacturing in the near future.
GenScript has offered solid support to the customer by shortening turnaround, improving quality and continuous research and garnered customer recognition, laying a foundation for further collaboration. This collaboration marks a major milestone for GenScript's presence in Thailand.
GenScript Biotech Corporation (HK.1548) is the world’s leading technology and service provider of life science R&D and manufacture. Built upon its solid gene synthesis technology, GenScript Biotech is divided into four major platforms including the life science service and product platform, the biologics contract development and manufacturing organization (CDMO) platform, the global cell therapy platform and the industrial synthesis biological product platform.
GenScript Biotech was founded in New Jersey, US in 2002 and listed on the Hong Kong Stock Exchange in 2015. GenScript Biotech's business operations span over 100 countries and regions worldwide with legal entities located in the US, Mainland China, Hong Kong, China, Japan, Singapore, the Netherlands and Ireland. GenScript Biotech provides premium, convenient and reliable services and products for over 200,000 customers.
As of June 30, 2022, GenScript Biotech had more than 5,500 employees globally, over 38% of whom hold master’s and/or Ph.D. degrees. In addition, GenScript Biotech owns a number of intellectual property rights, including over 190 patents, over 820 pending patent applications and great numbers of trade secrets.
Driven by the corporate mission of “make people and nature healthier through biotechnology”, GenScript Biotech strives to become the most trustworthy biotech company in the world. As of June 30, 2022, 74,700 peer-reviewed journal articles worldwide have cited GenScript Biotech’s services and products.
For more information, please visit GenScript Biotech's official website
Media Contacts:
Maggie Sun
Senior Director of Corporate Communications,
GenScript Biotech Corporation
[email protected]
